The chronic lymphocytic leukemias and chronic myeloproliferative
disorders are characterized by gradually increasing numbers of mature
cells in the bone marrow, usually involving the peripheral blood
and other organs.
Although none are rapidly fatal, hence the term chronic, they are difficult
to classify because of their varied, but often overlapping morphologic
and clinical characteristics. It is increasingly important to accurately
classify these disorders as new chemotheraputic agents and cytokine therapies